XML 49 R37.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and Contingencies - Additional Information (Details) - USD ($) |  |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 28, 2019 | Jan. 13, 2015 | Sep. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2017 | Nov. 28, 2020 | Oct. 22, 2019 | Feb. 19, 2019 | May 10, 2018 | Aug. 24, 2004
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  | $ 14,521,000 |  | $ 13,968,000 | $ 41,427,000 | $ 38,725,000 |  |  |  |  |  |  |
Cash balance |  |  | 91,725,000 |  |  | 91,725,000 |  | $ 115,069,000 |  |  |  |  |  |
Agreement commencement date |  |  |  |  |  |  |  |  | 2015-05 |  |  |  |  |
Expected Cash Payment Payable |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |  |  |
Minimum Royalties Amount Payable |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |
Annual Licensing fee paid |  |  | 0 |  |  |  |  |  |  |  |  |  |  |
Receivables |  |  | 1,510,000 |  |  | $ 1,510,000 |  | 4,665,000 |  |  |  |  |  |
Restricted stock awards |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  |
MD Anderson Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Warrants |  |  | 3,333,333 |  |  | 3,333,333 |  |  |  |  |  |  |  |
MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development service agreement aggregate quarterly payments |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |
Reimbursement of historical costs |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |
Aggregate potential benchmark payments |  |  |  |  |  |  |  |  |  |  | 36,500,000 |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |
Development costs incurred |  |  |  |  |  | 0 |  |  |  |  |  |  |  |
Development costs paid |  |  |  |  |  | 0 |  |  |  |  |  |  |  |
CRADA Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Obligations due under contract |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |
Quarterly payments under contract |  |  | $ 0 |  | 600,000 | 1,300,000 | 1,300,000 |  |  |  |  |  |  |
CAR Products [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of royalties receivable |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000.0 |
The University of Texas MD Anderson Cancer Center and The Texas A & M University System |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone maximum payment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,500,000
MD Anderson License |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables |  |  | 1,100,000 |  |  | 1,100,000 |  | 4,700,000 |  |  |  |  |  |
Accrued expenses |  |  | 2,100,000 |  |  | 2,100,000 |  | 1,400,000 |  |  |  |  |  |
License Agreement with the National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum Royalties Amount Payable |  |  | 300,000 |  |  | 300,000 |  |  |  |  |  |  |  |
payments under the Patent License |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |
License Agreement with the National Cancer Institute [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued payments or receipts |  |  | 100,000 |  |  | 100,000 |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected Cash Payment Payable | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Expected cash payment payable per installments | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum Royalties Amount Payable | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Description Of First Annual Royalty Payable | The first minimum annual royalty payment is payable on the date that is eighteen months following the date of the Patent License |  |  |  |  |  |  |  |  |  |  |  |  |
Description Of First Benchmark Payable | The first benchmark payment of $0.1 million will be due upon the initiation of the Company’s first sponsored Phase 1 clinical trial of a licensed product or licensed process in the field of use licensed under the Patent License, which has not been met at September 30, 2021. |  |  |  |  |  |  |  |  |  |  |  |  |
Description Of option To terminate Agreement | The NCI may terminate or modify the Patent License in the event of a material breach, including if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination, notice period | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |
payments under the Patent License |  |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  |
Annual Licensing fee paid |  |  |  |  | 0 | 0 | 0 |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | Performance Based Payments Member [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Benchmark Payments Payable | $ 4,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential Benchmark Payments Payable | 12,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | Post Marketing Approval [Member] | Performance Based Payments Member [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate Benchmark Payments Payable | 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Ziop License Agreement With The National Cancer Institute [Member] | licensed products [Member] | One Time Benchmark Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum Sales Revenue On Which Benchmark Payments Payable | $ 1,000,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Patent And Technology License Agreement [Member] | The University of Texas MD Anderson Cancer Center and The Texas A & M University System |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  | 80,000 |  |  | 80,000 |  |  |  |  |  |  |  |
Accrued payments |  |  |  |  | 0 |  | 0 |  |  |  |  |  |  |
Collaboration Agreement With Solasia Pharma KK [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued payments or receipts |  |  | 400,000 |  | 0 | 400,000 | 0 |  |  |  |  |  |  |
License Agreement With PGEN Therapeutics [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold |  |  | 0 |  | 0 | 100,000 | 0 |  |  |  |  |  |  |
Prepaid Expenses and Other Current Assets | MD Anderson License |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash balance |  |  | 0 |  |  | 0 |  |  |  |  |  |  |  |
Intrexon Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual License Fees |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |
Expected additional milestones payable |  |  |  |  |  |  |  |  |  |  |  |  | 52,500,000 |
Expected Cash Payment Payable |  |  |  |  |  |  |  | $ 100,000 |  |  |  |  |  |
Intrexon Corporation | T-cell receptor |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum royalty amount |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000.0 |
Portion of income payable to related party |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |
Minimum | License Agreement with the National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty fee |  |  | $ 300,000 |  | $ 0 |  | $ 0 |  |  |  |  |  |  |
Minimum | Ziop License Agreement With The National Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty fee |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |
Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_AccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-06(3)) -URI http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate value of stock related to Restricted Stock Awards issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Accrued Payments of TCR Products. + References No definition available. + Details
Name: | ziop_AccruedPaymentsOfTcrProducts
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Accrued payments or receipts under collaboration agreement. + References No definition available. + Details
Name: | ziop_AccruedPaymentsOrReceiptsUnderCollaborationAgreement
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Accrued payments under patent and technology license. + References No definition available. + Details
Name: | ziop_AccruedPaymentsUnderPatentAndTechnologyLicense
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate Amount Potentially Reimburseable Amount. + References No definition available. + Details
Name: | ziop_AggregateAmountPotentiallyReimburseableAmount
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents Aggregate Benchmark Payments Payable. + References No definition available. + Details
Name: | ziop_AggregateBenchmarkPaymentsPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential benchmark payments. + References No definition available. + Details
Name: | ziop_AggregatePotentialBenchmarkPayments
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Agreement termination notice period. + References No definition available. + Details
Name: | ziop_AgreementTerminationNoticePeriod
Namespace Prefix: | ziop_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual License Fees + References No definition available. + Details
Name: | ziop_AnnualLicenseFees
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments and Contingencies Disclosure [Line Items] + References No definition available. + Details
Name: | ziop_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | ziop_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents Description Of First Annual Royalty Payable. + References No definition available. + Details
Name: | ziop_DescriptionOfFirstAnnualRoyaltyPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents Description Of First Benchmark Payable. + References No definition available. + Details
Name: | ziop_DescriptionOfFirstBenchmarkPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones. + References No definition available. + Details
Name: | ziop_DescriptionOfOptionToTerminateTheAgreementUponNotMeetingCertainMilestones
Namespace Prefix: | ziop_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development costs incurred. + References No definition available. + Details
Name: | ziop_DevelopmentCostsIncurred
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development costs paid. + References No definition available. + Details
Name: | ziop_DevelopmentCostsPaid
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents Expected Cash Payment Payable. + References No definition available. + Details
Name: | ziop_ExpectedCashPaymentPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expected cash payment payable per installments. + References No definition available. + Details
Name: | ziop_ExpectedCashPaymentPayablePerInstallments
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement commencement date. + References No definition available. + Details
Name: | ziop_LicenseAgreementCommencementDate
Namespace Prefix: | ziop_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum amount of additional milestones payable. + References No definition available. + Details
Name: | ziop_MaximumAmountOfAdditionalMilestonesPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount of royalties receivable. + References No definition available. + Details
Name: | ziop_MaximumAmountOfRoyaltiesReceivable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of royalty payable. + References No definition available. + Details
Name: | ziop_MaximumAmountOfRoyaltyPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum Sales Revenue On Which Benchmark Payments Payable + References No definition available. + Details
Name: | ziop_MaximumSalesRevenueOnWhichBenchmarkPaymentsPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments maximum amount. + References No definition available. + Details
Name: | ziop_MilestonePaymentsMaximumAmount
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents Minimum Royalties Amount Payable. + References No definition available. + Details
Name: | ziop_MinimumRoyaltiesAmountPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Obligations due under contract. + References No definition available. + Details
Name: | ziop_ObligationsDueUnderContract
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment For Annual License Fees. + References No definition available. + Details
Name: | ziop_PaymentForAnnualLicenseFees
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments under patent license + References No definition available. + Details
Name: | ziop_PaymentsUnderPatentLicense
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of sub licensing income, attributable to related party. + References No definition available. + Details
Name: | ziop_PercentageOfSubLicensingIncomePayableToRelatedParty
Namespace Prefix: | ziop_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents Potential Benchmark Payments Payable. + References No definition available. + Details
Name: | ziop_PotentialBenchmarkPaymentsPayable
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Quarterly payments under contract. + References No definition available. + Details
Name: | ziop_QuarterlyPaymentsUnderContract
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development service agreement quarterly payment. + References No definition available. + Details
Name: | ziop_ResearchAndDevelopmentServiceAgreementQuarterlyPayment
Namespace Prefix: | ziop_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ziop_ClassOfWarrantOrRightAxisAxis=ziop_MdAndersonWarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ziop_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ziop_CRADAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ziop_CARProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ziop_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_MdAndersonLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_LicenseAgreementWithTheNationalCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ziop_PaymentTypeAxis=ziop_OneTimeBenchmarkPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_ZiopLicenseAgreementWithTheNationalCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ziop_PaymentTypeAxis=ziop_PerformanceBasedPaymentsMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ziop_DueDateAxis=ziop_PostMarketingApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ziop_LicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_PatentAndTechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_CollaborationAgreementWithSolasiaPharmaKkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ziop_LicenseAgreementWithPgenTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ziop_IntrexonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ziop_TcellReceptorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |